IL229226A0 - Pirfenidone and anti-fibrotic treatment in selected patients - Google Patents
Pirfenidone and anti-fibrotic treatment in selected patientsInfo
- Publication number
- IL229226A0 IL229226A0 IL229226A IL22922613A IL229226A0 IL 229226 A0 IL229226 A0 IL 229226A0 IL 229226 A IL229226 A IL 229226A IL 22922613 A IL22922613 A IL 22922613A IL 229226 A0 IL229226 A0 IL 229226A0
- Authority
- IL
- Israel
- Prior art keywords
- pirfenidone
- selected patients
- fibrotic therapy
- fibrotic
- therapy
- Prior art date
Links
- 230000003510 anti-fibrotic effect Effects 0.000 title 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title 1
- 229960003073 pirfenidone Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489936P | 2011-05-25 | 2011-05-25 | |
| US201161490057P | 2011-05-26 | 2011-05-26 | |
| US201161523047P | 2011-08-12 | 2011-08-12 | |
| US201161524961P | 2011-08-18 | 2011-08-18 | |
| PCT/US2012/039538 WO2012162592A1 (en) | 2011-05-25 | 2012-05-25 | Pirfenidone and anti-fibrotic therapy in selected patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL229226A0 true IL229226A0 (en) | 2014-01-30 |
Family
ID=47217770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL229226A IL229226A0 (en) | 2011-05-25 | 2013-11-04 | Pirfenidone and anti-fibrotic treatment in selected patients |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150164874A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2713732A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6170040B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140022048A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012258575B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835438A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1197159A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL229226A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013013752A (cg-RX-API-DMAC7.html) |
| SG (1) | SG195110A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012162592A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| BR112013022766A2 (pt) * | 2011-03-08 | 2016-12-06 | Auspex Pharmaceuticals Inc | método de administração de d-pirfenidona e kit |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| EP3194446B1 (en) * | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Compositions and methods for treating fibrosis |
| DK3050574T3 (da) * | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
| US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| SG11201907673YA (en) * | 2017-03-13 | 2019-09-27 | Genfit | Pharmaceutical compositions for combination therapy |
| US20210363259A1 (en) * | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| CA3140129A1 (en) * | 2019-05-17 | 2020-11-26 | The Regents Of The University Of California | Mps modified peptides and use thereof |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
| EP3821946A1 (en) * | 2019-11-12 | 2021-05-19 | Université de Strasbourg | Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| US20230129866A1 (en) * | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN114617890A (zh) * | 2020-12-08 | 2022-06-14 | 四川夏派森医药科技有限公司 | DH404在治疗SARS-CoV-2感染中的应用 |
| CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
| WO2023192646A1 (en) * | 2022-03-31 | 2023-10-05 | Puretech Lyt 100, Inc. | Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| CN1307997C (zh) * | 2002-06-28 | 2007-04-04 | 图兰恩教育基金管理人 | 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺 |
| WO2004103296A2 (en) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| WO2005110478A2 (en) * | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| WO2007119214A2 (en) * | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| HUE052220T2 (hu) * | 2006-09-08 | 2021-04-28 | Abbvie Bahamas Ltd | Interleukin-13 kötõfehérjék |
| AU2008265595B2 (en) * | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| EP2389227A4 (en) * | 2009-01-26 | 2012-08-08 | Intermune Inc | METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
-
2012
- 2012-05-25 AU AU2012258575A patent/AU2012258575B2/en not_active Ceased
- 2012-05-25 KR KR1020137028921A patent/KR20140022048A/ko not_active Ceased
- 2012-05-25 MX MX2013013752A patent/MX2013013752A/es not_active Application Discontinuation
- 2012-05-25 JP JP2014512134A patent/JP6170040B2/ja not_active Expired - Fee Related
- 2012-05-25 SG SG2013086541A patent/SG195110A1/en unknown
- 2012-05-25 HK HK14109929.1A patent/HK1197159A1/xx unknown
- 2012-05-25 EP EP12788732.1A patent/EP2713732A4/en not_active Withdrawn
- 2012-05-25 WO PCT/US2012/039538 patent/WO2012162592A1/en not_active Ceased
- 2012-05-25 US US14/373,276 patent/US20150164874A1/en not_active Abandoned
- 2012-05-25 CA CA2835438A patent/CA2835438A1/en not_active Abandoned
-
2013
- 2013-11-04 IL IL229226A patent/IL229226A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ617415A (en) | 2017-07-28 |
| US20150164874A1 (en) | 2015-06-18 |
| EP2713732A1 (en) | 2014-04-09 |
| JP6170040B2 (ja) | 2017-07-26 |
| WO2012162592A1 (en) | 2012-11-29 |
| JP2014518880A (ja) | 2014-08-07 |
| KR20140022048A (ko) | 2014-02-21 |
| HK1197159A1 (en) | 2015-01-09 |
| SG195110A1 (en) | 2013-12-30 |
| CA2835438A1 (en) | 2012-11-29 |
| EP2713732A4 (en) | 2014-12-03 |
| AU2012258575A1 (en) | 2013-11-21 |
| AU2012258575B2 (en) | 2017-03-02 |
| MX2013013752A (es) | 2014-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2013007178A0 (en) | BCMA-based stratification and therapy for multiplemyeloma patients | |
| EP2788075A4 (en) | DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| IL231386A (en) | Pyrazolequinoline derivatives, their preparation and medical use | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| EP2713732A4 (en) | PIRFENIDONE AND ANTIFIBROSETHERAPY IN SELECTED PATIENTS | |
| GB201218084D0 (en) | Novel compounds and methods for use in medicine | |
| EP2896294A4 (en) | MICRORNA IN HUMAN MILK AND USE THEREOF | |
| EP2934632B8 (en) | Device and method for inhibiting movement of a medical device in a patient | |
| SI2729469T1 (sl) | Derivati orvinola in tevinola uporabni pri zdravljenju zlorabe mamil in alkohola | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| GB2499241B (en) | Patient transport chair and track arrangement | |
| ZA201502153B (en) | Pyridinone compounds for use in photodynamic therapy | |
| PT2931716T (pt) | Derivados de piridona e suas utilizações no tratamento da tuberculose | |
| EP2706962A4 (en) | SURFACE CHARACTERISTICS OF DRUG RETENTION IN AN IMPLANTABLE MEDICAL DEVICE | |
| ZA201403477B (en) | Apricitabine and pi combination therapy | |
| GB201112260D0 (en) | Medical device and related methods | |
| GB201102221D0 (en) | Inventions and therapy | |
| GB201102213D0 (en) | Inventions and therapy | |
| GB201102226D0 (en) | Inventions and therapy | |
| GB201102239D0 (en) | Inventions and therapy | |
| GB201102234D0 (en) | Inventions and therapy | |
| GB201102216D0 (en) | Inventions and therapy | |
| GB201102208D0 (en) | Inventions and therapy |